165 related articles for article (PubMed ID: 27832697)
1. The Complete Response to Targeted Drugs Without Surgery or Radiotherapy: A Case of Pituitary Metastasis From Renal Cell Carcinoma.
Payandeh M; Sadeghi M; Sadeghi E
Acta Med Iran; 2016 Sep; 54(9):617-619. PubMed ID: 27832697
[TBL] [Abstract][Full Text] [Related]
2. Pituitary Metastasis from Renal Cell Carcinoma: Description of a Case Report.
Wendel C; Campitiello M; Plastino F; Eid N; Hennequin L; Quétin P; Longo R
Am J Case Rep; 2017 Jan; 18():7-11. PubMed ID: 28044054
[TBL] [Abstract][Full Text] [Related]
3. Metastatic renal cell carcinoma to the pituitary gland presenting with hypopituitarism.
Koshiyama H; Ohgaki K; Hida S; Takasu K; Yumitori K; Shimatsu A; Koh T
J Endocrinol Invest; 1992 Oct; 15(9):677-81. PubMed ID: 1479150
[TBL] [Abstract][Full Text] [Related]
4. Good response to second-line bevacizumab and interferon-alpha in a sunitinib-refractory patient with metastatic renal cell carcinoma.
Pastorelli D; Zustovich F; Faggioni G; Zovato S; Donach M; Nicoletto O; Farina M; Furini L; Ceravolo R; Carli P; Lombardi G
Anticancer Drugs; 2010 Feb; 21(2):210-3. PubMed ID: 19952729
[TBL] [Abstract][Full Text] [Related]
5. Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus.
Larkin JM; Fisher RA; Pickering LM; Sohaib SA; Ghosn M; Christmas T; Cordiner RL; Gore ME
J Clin Oncol; 2011 Mar; 29(9):e241-2. PubMed ID: 21245426
[No Abstract] [Full Text] [Related]
6. Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series.
Medioni J; Banu E; Helley D; Scotte F; Fournier L; Mejean A; Chedid A; Azizi M; Andrieu JM; Oudard S
Eur Urol; 2009 Jul; 56(1):207-11; quiz 211. PubMed ID: 19157688
[TBL] [Abstract][Full Text] [Related]
7. A 51-year-old man with rapidly progressive metastatic sarcomatoid renal cell carcinoma: an apparent complete clinical response to second-line therapy with sunitinib and low-dose interferon-alpha.
Bradshaw MJ; Cheville JC; Croghan GA
Clin Adv Hematol Oncol; 2011 Jan; 9(1):61-4. PubMed ID: 21326149
[No Abstract] [Full Text] [Related]
8. Complete response after sequential sunitinib-sorafenib treatment in a patient with renal cell carcinoma: a case report.
Verzoni E; Lanocita R; Procopio G
Clin Genitourin Cancer; 2012 Jun; 10(2):130-3. PubMed ID: 22226825
[No Abstract] [Full Text] [Related]
9. [First-line treatment for advanced renal cell carcinoma : A phase 3, open-label, randomized study of Atezolizumab (Anti-PD-L1-Antibody) in combination with Bevacizumab versus Sunitinib in patients with untreated advanced renal cell carcinoma ("IMmotion") - AN 37/15 der AUO].
Rexer H; Doehn C
Urologe A; 2016 Sep; 55(9):1242-3. PubMed ID: 27422311
[No Abstract] [Full Text] [Related]
10. Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma.
Di Nunno V; Mollica V; Corcioni B; Fiorentino M; Nobili E; Schiavina R; Golfieri R; Brunocilla E; Ardizzoni A; Massari F
Anticancer Drugs; 2018 Aug; 29(7):710-715. PubMed ID: 29846249
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma.
Rini BI; Stein M; Shannon P; Eddy S; Tyler A; Stephenson JJ; Catlett L; Huang B; Healey D; Gordon M
Cancer; 2011 Feb; 117(4):758-67. PubMed ID: 20922784
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma.
Keizman D; Ish-Shalom M; Pili R; Hammers H; Eisenberger MA; Sinibaldi V; Boursi B; Maimon N; Gottfried M; Hayat H; Peer A; Kovel S; Sella A; Berger R; Carducci MA
Eur J Cancer; 2012 May; 48(7):1031-7. PubMed ID: 22409947
[TBL] [Abstract][Full Text] [Related]
13. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Golshayan AR; George S; Heng DY; Elson P; Wood LS; Mekhail TM; Garcia JA; Aydin H; Zhou M; Bukowski RM; Rini BI
J Clin Oncol; 2009 Jan; 27(2):235-41. PubMed ID: 19064974
[TBL] [Abstract][Full Text] [Related]
14. [Not Available].
Aktuelle Urol; 2015 Sep; 46(5):356-7. PubMed ID: 26394083
[No Abstract] [Full Text] [Related]
15. Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
Levy A; Menard J; Albiges L; Loriot Y; Di Palma M; Fizazi K; Escudier B
Eur J Cancer; 2013 May; 49(8):1898-904. PubMed ID: 23490648
[TBL] [Abstract][Full Text] [Related]
16. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
[TBL] [Abstract][Full Text] [Related]
17. Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study.
Atkins MB; Gravis G; Drosik K; Demkow T; Tomczak P; Wong SS; Michaelson MD; Choueiri TK; Wu B; Navale L; Warner D; Ravaud A
J Clin Oncol; 2015 Oct; 33(30):3431-8. PubMed ID: 26304872
[TBL] [Abstract][Full Text] [Related]
18. [A case of complete response of multiple lung metastases of renal cell carcinoma with the flexible administration of sunitinib].
Kim H; Shoji S; Usui Y; Nagata Y; Terachi T; Uchida T
Hinyokika Kiyo; 2013 Jan; 59(1):7-10. PubMed ID: 23412117
[TBL] [Abstract][Full Text] [Related]
19. Combination of targeted agents in metastatic renal cell carcinoma: a path forward or a dead-end street?
Michaelson MD
Cancer; 2012 Apr; 118(7):1744-6. PubMed ID: 21898374
[No Abstract] [Full Text] [Related]
20. A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma.
Richards TM; Plowman PN; Reznek R; Ball SA
Clin Oncol (R Coll Radiol); 2009 Oct; 21(8):633-4. PubMed ID: 19380217
[No Abstract] [Full Text] [Related]
[Next] [New Search]
